# Edoxaban -- leave title blank below
#+TITLE:  
#+AUTHOR:    David Mann
#+EMAIL:     mannd@epstudiossoftware.com
#+DATE:      [2015-02-23 Mon]
#+DESCRIPTION:
#+KEYWORDS:
#+LANGUAGE:  en
#+OPTIONS:   H:3 num:nil toc:nil \n:nil @:t ::t |:t ^:t -:t f:t *:t <:t
#+OPTIONS:   TeX:t LaTeX:t skip:nil d:nil todo:t pri:nil tags:not-in-toc
#+INFOJS_OPT: view:nil toc:nil ltoc:t mouse:underline buttons:0 path:http://orgmode.org/org-info.js
#+EXPORT_SELECT_TAGS: export
#+EXPORT_EXCLUDE_TAGS: noexport
#+LINK_UP:   
#+LINK_HOME: 
#+XSLT:
* Dosage and administration
** Nonvalvular atrial fibrillation
| CrCl              | Dose                |
|-------------------+---------------------|
| >95 mL/min        | DO NOT USE!         |
| >50 to ≤95 mL/min | 60 mg PO once daily |
| ≥15 to <50 mL/min | 30 mg PO once daily |
| <15 mL/min        | DO NOT USE!         |
Note: Do not use with CrCl >95 mL/min!
** DVT and PE
| CrCl              | Dose                    |
|-------------------+-------------------------|
| >50 mL/min        | 60 mg orally once daily |
| ≥15 to <50 mL/min | 30 mg orally once daily |
Patients with body weight ≤60 kg or receiving certain P-gp inhibitors (verpamil, quinidine, azithromycin, clarithromycin, erhythromycin, itraconazole or ketoconazole) use 30 mg once daily.
* Dosage forms and strengths
- Tablets
  - 15 mg
  - 30 mg
  - 60 mg
* Contraindications
-  Active pathological bleeding
* Warnings and precautions
- Bleeding: serious and potentially fatal bleeding.  Promptly evaluate signs and symptoms of blood loss.
- Mechanical heart valves or moderate to severe mitral stenosis: Use is not recommended.
* Adverse reactions
- Treatment of nonvalvular AF: The most common adverse reactions (≥5%) are bleeding and anemia.
- Treatment of DVT and PE: The most common adverse reactions (≥1%) are bleeding, rash, abnormal liver function tests and anemia.
* Drug interactions
- Anticoagulants: Avoid concomitant use.
- Rifampin: Avoid concomitant use.
* Use in specific populations
- Nursing mothers: Discontinue drug or discontinue nursing.
- Impaired renal function: Reduce dose (see tables above).
- Moderate or severe hepatic impairment: Not recommended.
